Ionetix | Leading Radiopharmaceuticals & Targeted Alpha Therapy
IONETIX ION-12SC cyclotron

Take Control

CYCLOTRON SOLUTIONS OPERATIONAL SOLUTIONS CGMP SOLUTIONS
Find out more→

Where clinical excellence meets business opportunity

N13 Ammonia paves the way to better diagnostics

View attributes→
Diagnostics

N13 Ammonia paves the way to better diagnostics

View attributes → Targeted Alpha Therapy

Therapeutic alpha radionuclides for use in Targeted Alpha Therapy

Learn more → Education

Need CE Credits? View our PET Educational Series

Learn more →

Diagnostics & Therapeutics

Diagnostics & Therapeutics→
N-13 Ammonia cardiac PET imaging

N-13 Ammonia

Explore →
PSMA PET imaging

Ga-68 PSMA-11

Explore →
Astatine 211

Astatine 211

Explore →
Actinium 225

Actinium 225

Explore →
Ionetix Completes $30 million+ Financing in a Go-Public Transaction
Featured story

Ionetix Completes $30 million+ Financing in a Go-Public Transaction

April 21, 2026 View News & Events →

Latest News

View News & Events→
Ionetix Appoints Paul Surdez as Head of Investor Relations August 17, 2026

Ionetix Appoints Paul Surdez as Head of Investor Relations

 Ionetix Announces Approval of Abbreviated New Drug Application for Gallium Ga-68 Gozetotide (PSMA-11) May 26, 2026

Ionetix Announces Approval of Abbreviated New Drug Application for Gallium Ga-68 Gozetotide (PSMA-11)

 Ionetix Completes $30 million+ Financing in a Go-Public Transaction April 21, 2026

Ionetix Completes $30 million+ Financing in a Go-Public Transaction

Harness the power to deliver advanced radiopharmaceuticals

The time is now to partner with us to gain access to scarce diagnostics and therapeutic radiopharmaceuticals.

Get started now→